Keyword: Darzalex

Drugmakers have hoped that pairing their cancer drugs with I-O treatments would improve benefits. Not for Genmab and J&J.

Johnson & Johnson’s Darzalex just vaulted ahead of its myeloma competitors—and it has plenty of them.

While Johnson & Johnson’s multiple myeloma drug Darzalex has steadily won new approvals from the FDA, it continues to face obstacles in England.

J&J has succeeded in moving Darzalex earlier into multiple myeloma therapy, and it now has data that could help it win a first-line nod.

Johnson & Johnson may eventually tire of shelling out Darzalex payments to Genmab and take matters into its own hands, one analyst says.

Late last year, Johnson & Johnson widened Darzalex’s reach with some combo approvals. And now, it’s adding to that roster.

J&J missed analyst expectations on pharma and consumer health sales in the first quarter as some of its stalwart performers shrank instead of grew.

J&J and Genmab have hit a snag in their quest for Darzalex expansion, throwing in the towel on a non-Hodgkin’s lymphoma trial.

There are big expectations for Johnson & Johnson multiple myeloma drug Darzalex. But England's drug price watchdog is dampening its earnings potential there.

Ever since Bristol-Myers won FDA approval for Opdivo, it's been busy locking up partnerships to test the immuno-oncology med in combo cocktails. Now it’s expanding its alliance with J&J.